Solid Biosciences (SLDB) Competitors $5.62 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$5.62 0.00 (-0.09%) As of 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SLDB vs. CDTX, DYN, APGE, IMCR, BEAM, TWST, TVTX, AUPH, WVE, and EWTXShould you be buying Solid Biosciences stock or one of its competitors? The main competitors of Solid Biosciences include Cidara Therapeutics (CDTX), Dyne Therapeutics (DYN), Apogee Therapeutics (APGE), Immunocore (IMCR), Beam Therapeutics (BEAM), Twist Bioscience (TWST), Travere Therapeutics (TVTX), Aurinia Pharmaceuticals (AUPH), WAVE Life Sciences (WVE), and Edgewise Therapeutics (EWTX). These companies are all part of the "pharmaceutical products" industry. Solid Biosciences vs. Its Competitors Cidara Therapeutics Dyne Therapeutics Apogee Therapeutics Immunocore Beam Therapeutics Twist Bioscience Travere Therapeutics Aurinia Pharmaceuticals WAVE Life Sciences Edgewise Therapeutics Cidara Therapeutics (NASDAQ:CDTX) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings. Which has preferable valuation and earnings, CDTX or SLDB? Cidara Therapeutics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCidara TherapeuticsN/AN/A-$169.83M-$11.13-5.86Solid BiosciencesN/AN/A-$124.70M-$2.80-2.01 Does the media refer more to CDTX or SLDB? In the previous week, Solid Biosciences had 2 more articles in the media than Cidara Therapeutics. MarketBeat recorded 4 mentions for Solid Biosciences and 2 mentions for Cidara Therapeutics. Cidara Therapeutics' average media sentiment score of 1.83 beat Solid Biosciences' score of 1.63 indicating that Cidara Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cidara Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Solid Biosciences 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do institutionals and insiders believe in CDTX or SLDB? 35.8% of Cidara Therapeutics shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 3.9% of Cidara Therapeutics shares are owned by insiders. Comparatively, 1.9% of Solid Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Do analysts prefer CDTX or SLDB? Cidara Therapeutics presently has a consensus target price of $64.14, indicating a potential downside of 1.67%. Solid Biosciences has a consensus target price of $15.00, indicating a potential upside of 166.90%. Given Solid Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Solid Biosciences is more favorable than Cidara Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cidara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11Solid Biosciences 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 2 Strong Buy rating(s) 3.17 Which has more volatility and risk, CDTX or SLDB? Cidara Therapeutics has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500. Comparatively, Solid Biosciences has a beta of 2.44, meaning that its stock price is 144% more volatile than the S&P 500. Is CDTX or SLDB more profitable? Cidara Therapeutics' return on equity of -50.81% beat Solid Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Cidara TherapeuticsN/A -50.81% -42.46% Solid Biosciences N/A -69.70%-56.74% SummarySolid Biosciences beats Cidara Therapeutics on 10 of the 14 factors compared between the two stocks. Get Solid Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SLDB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLDB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLDB vs. The Competition Export to ExcelMetricSolid BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$437.62M$3.06B$5.76B$9.84BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-2.0121.2231.3126.60Price / SalesN/A390.30461.30121.37Price / CashN/A44.4437.7659.36Price / Book1.698.0710.026.67Net Income-$124.70M-$54.08M$3.27B$265.59M7 Day Performance-0.71%2.26%3.17%3.42%1 Month Performance-19.94%3.42%4.34%1.09%1 Year Performance-35.77%18.61%44.11%23.85% Solid Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLDBSolid Biosciences3.3549 of 5 stars$5.62flat$15.00+166.9%-38.6%$437.62MN/A-2.01100CDTXCidara Therapeutics3.6357 of 5 stars$67.43+3.7%$64.14-4.9%+404.2%$1.75B$1.27M-6.2190Positive NewsDYNDyne Therapeutics3.5762 of 5 stars$11.94-0.3%$33.80+183.2%-69.0%$1.70BN/A-3.10100Positive NewsAnalyst UpgradeAPGEApogee Therapeutics3.7671 of 5 stars$36.58+1.5%$99.00+170.7%-20.5%$1.68BN/A-8.8491Positive NewsAnalyst ForecastIMCRImmunocore1.5813 of 5 stars$32.91+1.3%$58.00+76.2%-9.7%$1.67B$310.20M-82.86320Positive NewsAnalyst ForecastBEAMBeam Therapeutics2.04 of 5 stars$15.91-0.9%$48.45+204.5%-35.9%$1.61B$63.52M-3.55510Positive NewsTWSTTwist Bioscience3.9416 of 5 stars$26.63+0.7%$49.40+85.5%-39.7%$1.61B$312.97M-18.37990Positive NewsTVTXTravere Therapeutics2.3489 of 5 stars$17.83-0.8%$32.21+80.7%+92.5%$1.60B$233.18M-8.78460Positive NewsAnalyst ForecastGap UpAUPHAurinia Pharmaceuticals2.9997 of 5 stars$11.98-0.2%$12.00+0.2%+79.9%$1.58B$235.13M27.90300Positive NewsWVEWAVE Life Sciences4.7744 of 5 stars$9.67+2.3%$20.27+109.7%+78.4%$1.54B$108.30M-10.77240Insider TradeEWTXEdgewise Therapeutics2.3223 of 5 stars$14.43+4.2%$40.55+181.0%-26.9%$1.53BN/A-9.3760 Related Companies and Tools Related Companies Cidara Therapeutics Competitors Dyne Therapeutics Competitors Apogee Therapeutics Competitors Immunocore Competitors Beam Therapeutics Competitors Twist Bioscience Competitors Travere Therapeutics Competitors Aurinia Pharmaceuticals Competitors WAVE Life Sciences Competitors Edgewise Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLDB) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredWhat Are Some Strategies to Help Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Solid Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Solid Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access